The central Massachusetts nonprofit’s aim is to improve population health, but its partnership with Google on data management and AI should also lower costs.
UMass Memorial, Google Cloud partner to connect patients with cardiometabolic drugs Read More »
En el desafiante mundo de la industria, mantener una temperatura adecuada en los espacios de trabajo no solo es una cuestión de confort, sino también un pilar fundamental para la eficiencia operativa. La climatización afecta directamente la productividad, la calidad del producto …
La solución más eficiente para la climatización industrial Read More »
Innate Pharma SA announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.
Seattle Children’s Research Institute, the research division of Seattle Children’s Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children’s Research Institute’s X-linked agammaglobulinemia program.
Innate Pharma SA announced the first patient was dosed in its Phase 1/2 multicenter trial, investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.
Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, will publish its 2023 financial results on March 14, 2024, at 7.30am CET.
Akeso Inc. announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab combined with chemotherapy versus Tislelizumab combined with chemotherapy in the first-line treatment for patients with PD-L1 negative non-small cell lung cancer.
Medivir AB announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024.
Medivir to present at Swiss Nordic Bio in Zürich on March 7 Read More »
GenSight Biologics announced that recent prospective real-world data from early access programs confirm the benefit of LUMEVOQ® in patients with Leber Hereditary Optic Neuropathy from the ND4 mutation, as observed in clinical trials.
Tandem Diabetes Care, Inc. announced the pricing of $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
